| Bioactivity | Anagrelide, an inhibitor of phosphodiesterase type III (PDEIII) (IC50=36 nM), inhibits platelet production. Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide plays in the antithrombopoietic action. The platelet-lowering agent[1]. |
| Target | PDEIII |
| Invitro | Anagrelide potently inhibits the development of marrow megakaryocytes (IC50=26 nM)[1].Anagrelide is a distinct pharmacological agent that inhibit bone marrow megakaryocytopoiesis. Anagrelide (0.05, 0.3, 1 µM) inhibits only megakaryocytic cell growth not non-megakaryocytic cells. Anagrelide shifts cell growth to the non-megakaryocytic compartment, an effect that suggested that it was devoid of cytotoxic activity[2].Anagrelide induces a cytotoxic effect in the GIST882 cell line at a submicromolar concentration (IC50= 16 nM), but Anagrelide is only weakly active in the GIST48 cell line[3].Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro[3]. Cell Proliferation Assay[2] Cell Line: |
| In Vivo | Anagrelide is effective in a GIST xenograft mouse model with KIT exon 9 mutation that may pose a therapeutic challenge, as these GISTs require a high daily dose of Imatinib[3].Anagrelide inhibits GIST growth in patient-derived mouse xenograft models. Anagrelide has therapeutic value in the treatment of GIST.Anagrelide has antitumoral activity in GIST xenograft models[3]. Anagrelide (5 mg/kg/bid) inhibits or reduces tumor growth in GIST2B, GIST9, GIST882 model models[3]. Animal Model: |
| Name | Anagrelide |
| CAS | 68475-42-3 |
| Formula | C10H7Cl2N3O |
| Molar Mass | 256.09 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Guosu Wang, et al. Comparison of the biological activities of Anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005 Oct;146(3):324-32. [2]. Y Hong, et al. Comparison between Anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of Anagrelide for the megakaryocytic lineage. Leukemia. 2006 Jun;20(6):1117-22. [3]. Olli-Pekka Pulkka, et al. Anagrelide for Gastrointestinal Stromal Tumor. Clin Cancer Res. 2019 Mar 1;25(5):1676-1687. |
Anagrelide
CAS: 68475-42-3 F: C10H7Cl2N3O W: 256.09
Anagrelide, an inhibitor of phosphodiesterase type III (PDEIII) (IC50=36 nM), inhibits platelet production. Anagrelide,
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.